These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2447203)

  • 1. Evidence of a relationship between high serum CA 125 and liver failure pattern in cirrhotic patients without ascitis and jaundice.
    Ruibal A; Siuriana R
    Int J Biol Markers; 1986; 1(1):55-6. PubMed ID: 2447203
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of hepatic dysfunction and bilirubin on CA 19-9 levels in cirrhotic patients.
    Leandro G; Zizzari S; Manghisi OG
    Gastroenterology; 1987 Jan; 92(1):270-1. PubMed ID: 3465665
    [No Abstract]   [Full Text] [Related]  

  • 3. [Comparison of CA 50 and CA 19-9 tumor markers in benign and malignant diseases of the upper gastrointestinal tract].
    Heptner G; Domschke S; Schneider MU; Siegfried W; Domschke W
    Dtsch Med Wochenschr; 1986 Mar; 111(10):374-8. PubMed ID: 2419074
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study of the tumor marker carbohydrate antigen 50 in liver cirrhosis. Pathogenetic considerations.
    Collazos J; Genolla J; Ruibal A
    Clin Nucl Med; 1993 Jan; 18(1):56-9. PubMed ID: 8422722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Serum levels and clinical evaluation of CA 19-9 in various diseases].
    Toyama K; Noto M; Sakaguchi T; Adachi K; Mitomi H; Okada N; Ootaka H; Nakazawa H; Hara E
    Gan No Rinsho; 1985 Mar; 31(3):293-8. PubMed ID: 2582158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Increase in serum mucin-like carcinoma-associated antigen (MCA) in patients with chronic liver diseases].
    Soriano A; Pombo L; Sagredo E; Ruibal A
    Med Clin (Barc); 1988 Nov; 91(17):675. PubMed ID: 3230974
    [No Abstract]   [Full Text] [Related]  

  • 7. CA-19-9 and CEA in the differential diagnosis of isolated liver metastases compared to clinical laboratory tests.
    Lorenz M; Hottenrott C; Baum RP; Maul FD; Kirkowa-Reimann M; Hör G; Encke A
    Nucl Med Commun; 1987 Oct; 8(10):787-96. PubMed ID: 3481063
    [No Abstract]   [Full Text] [Related]  

  • 8. [Significance of the serum levels of Ca 19-9 and CA 50 in gastric cancer].
    Loizate Totorikaguena A; Lamiquiz Vallejo A; Domínguez Merru-Urrutia MJ
    Rev Esp Enferm Apar Dig; 1987 Nov; 72(5 Pt 2):644-5. PubMed ID: 2452465
    [No Abstract]   [Full Text] [Related]  

  • 9. Serum levels of CA 50 in nonmalignant liver diseases: a clinical and biochemical study.
    Collazos J; Genolla J; Ruibal A
    Am J Gastroenterol; 1993 Mar; 88(3):409-12. PubMed ID: 8438849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An initial appraisal of the value of serum carbohydrate antigenic determinant (CA 19-9) levels in patients with pancreatic cancer.
    Buamah PK; Cornell C; Venables CW; Skillen AW
    Eur J Cancer Clin Oncol; 1987 Jan; 23(1):87-91. PubMed ID: 2439345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Correlation between CA 19-9 and Lewis antigen in blood].
    Fujiki T; Takeuchi M
    Nihon Shokakibyo Gakkai Zasshi; 1985 Aug; 82(8):1977. PubMed ID: 2415732
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis of a differential functional pattern between non-cirrhotic chronic liver disease and hepatic cirrhosis: a multivariate approach.
    Coltorti M; Colombi A; Lucchelli PE; Budillon G; Di Simone A; Carrella M; Oriani GA
    Rev Int Hepatol; 1969; 19(7):451-73. PubMed ID: 4102238
    [No Abstract]   [Full Text] [Related]  

  • 13. CA-125: An evaluation.
    Nuss R; Swor MG; Benrubi MD
    J Fla Med Assoc; 1987 May; 74(5):329-32. PubMed ID: 2440975
    [No Abstract]   [Full Text] [Related]  

  • 14. Caffeine elimination in cirrhotic and non-cirrhotic liver disease of different etiology.
    Joeres R; Brachtel D; Gallenkamp H; Hofstetter G; Klinker H; Zilly W; Richter E
    Z Gastroenterol; 1993 Feb; 31 Suppl 2():56-61. PubMed ID: 7483716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CA-125 and endometriosis.
    Barbieri RL
    Contrib Gynecol Obstet; 1987; 16():103-8. PubMed ID: 2446822
    [No Abstract]   [Full Text] [Related]  

  • 16. Elevation of serum CA 125 prior to diagnosis of an epithelial ovarian carcinoma.
    Bast RC; Siegal FP; Runowicz C; Klug TL; Zurawski VR; Schonholz D; Cohen CJ; Knapp RC
    Gynecol Oncol; 1985 Sep; 22(1):115-20. PubMed ID: 2410329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoembryonic antigen(s) in liver disease. I. Clinical and morphological studies.
    Moore T; Dhar P; Zamcheck N; Keeley A; Gottlieb L; Kupchik HZ
    Gastroenterology; 1972 Jul; 63(1):88-94. PubMed ID: 4115635
    [No Abstract]   [Full Text] [Related]  

  • 18. CA 50 serum levels in patients with liver diseases.
    Genolla J; Moragas G; Mañe S; Rosell M; Cuartero A; Encabo G; Ruibal A
    Int J Biol Markers; 1987; 2(3):207-8. PubMed ID: 2836527
    [No Abstract]   [Full Text] [Related]  

  • 19. [Comparative evaluation of tolerance tests with sulfobromophthalein and with galactose in chronic liver diseases. (Value and limitations of the discriminating analyses used in the 2 tests for diagnosis of hepatic cirrhosis)].
    Coltorti M; Di Simone A; Budillon G; Carrella M; Oriani G
    Policlinico Med; 1968; 75(4):189-215. PubMed ID: 5708459
    [No Abstract]   [Full Text] [Related]  

  • 20. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
    Bray KR; Koda JE; Gaur PK
    Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.